Femoston 1/10 & 2/10/Femoston Conti 1/5

Femoston 1/10 & 2/10/Femoston Conti 1/5


estradiol + dydrogesterone




Zuellig Pharma
Concise Prescribing Info
Femoston 1/10: 14 white FC tab each containing Estradiol 1 mg, 14 grey FC tab each containing Estradiol 1 mg, dydrogesterone 10 mg. Femoston 2/10: 14 orange FC tab each containing Estradiol 2 mg, 14 yellow FC tab each containing Estradiol 2 mg, dydrogesterone 10 mg. Femoston Conti 1/5: Each salmon tab containing Estradiol 1 mg, dydrogesterone 5 mg
Dosage/Direction for Use
Hormone replacement therapy for women w/ disorders due to natural or surgically induced menopause w/ intact uteri Femoston 1/10 1 white tab daily for 1st 14 days, followed by 1 grey tab daily for the next 14 days. Femoston 2/10 1 orange tab daily for 1st 14 days, followed by 1 yellow tab daily for the next 14 days, continue w/o interruption. If patient is still menstruating, begin treatment on 1st day after onset of menstruation. Hormone replacement therapy for the relief of symptoms due to estrogen deficiency & prevention of postmenopausal osteoporosis in women >12 mth after menopause w/ a uterus Femoston Conti 1/5 1 tab daily, taken continuously w/o break between packs, use only in postmenopausal women >12 mth after menopause.
May be taken with or without food.
Hypersensitivity. History &/or confirmed active venous thromboembolism (DVT, pulmonary embolism) w/in the last 2 yr. History of recurrent venous thromboembolism (VTE) or known thrombophilic disease in patients who are not already on anticoagulant treatment. Active or recent arterial thromboembolic disease. Diagnosed, suspected or past history of breast cancer, endometrial carcinoma or other hormone-dependent neoplasia. Acute or chronic liver disease. History of liver disease where the liver function tests have not returned to normal. Abnormal or undiagnosed vag bleeding. Known or suspected pregnancy. Femoston Conti 1/5 Cerebral vascular accident. Lactation.
Special Precautions
Periodic general & gynaecological exam & mammogram should be instituted. Epilepsy, migraine, cardiac failure, HTN, porphyria, haemoglobinopathies, otosclerosis, uterine fibroids/leiomyomata. Endometriosis. Femoston 1/10/Femoston 2/10 Not intended for contraceptive use. Patients in perimenopausal phase are advised to take nonhormonal contraceptive precautions. Interruption of hormone replacement therapy 1 mth before surgery should be considered. Lactation. Femoston Conti 1/5 History of thromboembolic disorders or presence of risk factors eg, history of recurrent VTE or known thrombophilic states, severe obesity, SLE; multiple sclerosis, asthma, liver disease, renal dysfunction, diabetes.
Adverse Reactions
Breast tenderness. Headache, oedema. Breakthrough bleedings, skin reactions. Femoston 1/10/Femoston 2/10 Nausea. Femoston Conti 1/5 Spotting, dysmenorrhoea, premenstrual-like syndrome, increased size of uterine fibroids, vag candidiasis, change in cervical erosion & degree of cervical secretion, cystitis-like syndrome, breast enlargement, GI disturbances, steepening of corneal curvature, contact lens intolerance, migraine, dizziness, mental depression, chorea, increased or decreased wt, changes in carbohydrate metabolism, aggravation of porphyria, changes in libido, leg cramps.
Drug Interactions
Reduced estrogen effect w/ liver enzyme inducers eg, oxcarbazepine, topiramate, felbamate, barbiturates, phenytoin, rifampicin, carbamazepine.
ATC Classification
G03FB08 - dydrogesterone and estrogen ; Belongs to the class of progestogens and estrogens in sequential preparations.
Femoston 2/10 FC tab
Femoston Conti 1/5 FC tab
(salmon) 28's
Femoston 1/10 FC tab
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in